Mangalam Drugs Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

The Mangalam Drugs stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Mangalam Drugs share price prediction as one data point and not as a guarantee of future performance.

This article reviews every dimension of the Mangalam Drugs stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

What Analysts Predict for Mangalam Drugs Stock in 2026

Analyst consensus on the Mangalam Drugs stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and Kotak Securities. All figures are sourced from publicly available research and should be verified before publishing.

Brokerage	Rating	Mangalam Drugs Stock Prediction (Rs)	Updated
JM Financial	Neutral	Rs 298	2026
Kotak Securities	Neutral	Rs 272	2026
Analyst Consensus	–	Rs 285	2026

The analyst target range for Mangalam Drugs reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Mangalam Drugs stock forecast from the current price of Rs 250 may or may not be realised by end of 2026.

Mangalam Drugs Company Overview

Mangalam Drugs and Organics is a significant player in India's pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Mangalam Drugs stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.

Metric	Value
NSE Ticker	MANGDRUGS
Sector	Pharmaceuticals and Healthcare
CMP	Rs 250 (2026)
52 Week High	–
52 Week Low	–
Market Cap	–
P/E Ratio	–
Mangalam Drugs Stock Prediction Consensus (12M)	Rs 285

Mangalam Drugs Stock Prediction by Time Horizon

Analysts split the Mangalam Drugs share price prediction across time frames as near-term drivers differ materially from the long-term view.

Short-Term Mangalam Drugs Stock Prediction

The near-term Mangalam Drugs stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 250 are being watched closely. A short-term Mangalam Drugs share price prediction carries the most uncertainty of any time horizon.

12-Month Mangalam Drugs Stock Prediction

JM Financial targets Rs 298 (Neutral) and Kotak Securities targets Rs 272 (Neutral). Most desks refresh their Mangalam Drugs stock forecast within two to four weeks of each quarterly earnings print. The Mangalam Drugs share price prediction should be verified against the most recent analyst reports.

Long-Term Mangalam Drugs Stock Prediction

The long-term outlook for Mangalam Drugs is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. Long-term price targets carry the most uncertainty and should be treated as directional guidance only.

Mangalam Drugs Stock Forecast: Key Factors

The following four factors appear consistently in analyst research on Mangalam Drugs and are the primary inputs into the bull and bear case scenarios.

US Generic Revenue

US generics revenue is the most watched metric in the Mangalam Drugs stock forecast. USFDA approval timelines and price erosion rates directly affect the Mangalam Drugs share price prediction from most research desks.

Domestic Formulations Growth

Domestic formulation growth provides a stable base that supports the Mangalam Drugs stock prediction even when export growth faces headwinds.

R&D Pipeline

The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Mangalam Drugs share price prediction. New product approvals are cited as catalysts for the Mangalam Drugs stock prediction.

EBITDA Margin

Sustained EBITDA margin expansion is typically the basis for the bullish Mangalam Drugs stock forecast. Margin recovery strengthens the Mangalam Drugs share price prediction from most research desks.

Mangalam Drugs Stock Prediction: Bull and Bear Scenarios

Scenario	Mangalam Drugs Stock Prediction	Key Conditions
Bull Case	Rs 298	Strong execution, margin improvement, favourable macro and sector re-rating
Base Case	Rs 285	Steady performance, gradual recovery, margins hold, growth on track
Bear Case	Rs 242	Demand deterioration, margin pressure, sector de-rating and macro headwinds

The bull case Mangalam Drugs stock forecast of Rs 298 assumes most positive variables converge. The base case of Rs 285 is the analyst consensus and may or may not be achieved.

How Analysts Are Reading the Mangalam Drugs Stock Story

Analyst reviews of the Mangalam Drugs share price prediction highlight the company's core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the analyst consensus for Mangalam Drugs is built on real business strengths set against real risks.

Key Risks to the Mangalam Drugs Stock Prediction

USFDA Regulatory Risk

Import alerts and warning letters from the USFDA are the most significant risks to the Mangalam Drugs stock prediction. A facility closure would force an immediate sharp revision to the Mangalam Drugs share price prediction.

Price Erosion in the US

Pricing pressure in US generics compresses the revenue per product and affects the Mangalam Drugs stock forecast. Aggressive price erosion pushes the Mangalam Drugs share price prediction toward the bear case.

R&D Execution Risk

Delays in clinical trials or approval failures affect the Mangalam Drugs stock prediction. The Mangalam Drugs share price prediction is particularly sensitive to key pipeline asset announcements.

Currency Risk

A strengthening rupee against the dollar reduces export realisation and affects the Mangalam Drugs stock forecast. Currency risk is embedded in conservative Mangalam Drugs share price prediction models.

How to Monitor the Mangalam Drugs Stock Forecast

Track the Mangalam Drugs share price prediction consensus quarterly. After every earnings release, most brokerages revise their Mangalam Drugs stock forecast within two weeks. Comparing the revised analyst target to the previous estimate tells you whether sentiment on Mangalam Drugs is improving or deteriorating.

Compare the current price of Rs 250 with the analyst target range of Rs 298 to Rs 272. A wide target band reflects genuine uncertainty on Mangalam Drugs, so position size should reflect that range rather than the midpoint alone.

Review the Mangalam Drugs share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.

Check Live Mangalam Drugs Fundamentals on the Univest Screener

Conclusion

The Mangalam Drugs stock prediction for 2026 reflects the analyst community's assessment of Mangalam Drugs and Organics's competitive position, earnings trajectory and macro environment. JM Financial holds a Neutral stance with a target of Rs 298 while Kotak Securities has a Neutral rating with a target of Rs 272, giving an analyst consensus of Rs 285.

The Mangalam Drugs stock forecast is set against near-term risks that make the Mangalam Drugs share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking how the Mangalam Drugs share price target changes over time is more valuable than relying on any single estimate.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Download the Univest iOS App or Univest Android App to track live analyst targets, price movements and research updates for Mangalam Drugs in real time.

Frequently Asked Questions on Mangalam Drugs Stock Prediction 2026

What is the Mangalam Drugs stock prediction for 2026?

Ans. The Mangalam Drugs stock prediction for 2026 is based on analyst consensus from JM Financial and Kotak Securities. The consensus target is Rs 285. All estimates may or may not be achieved.

Is the Mangalam Drugs stock prediction bullish or bearish?

Ans. JM Financial has a Neutral rating with target Rs 298. Kotak Securities has a Neutral rating with target Rs 272. The Mangalam Drugs stock forecast reflects genuine analyst diversity of opinion.

What is the Mangalam Drugs share price prediction based on fundamentals?

Ans. The Mangalam Drugs share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Mangalam Drugs closely cite these as the primary drivers of the 2026 outlook.

What is the long-term Mangalam Drugs stock prediction?

Ans. The long-term outlook assumes Mangalam Drugs sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 285 is the nearest reliable anchor point.

What are the key risks to the Mangalam Drugs stock prediction?

Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every analyst estimate for Mangalam Drugs should be read alongside its risk assumptions.

What does the Mangalam Drugs stock forecast say for 2026?

Ans. JM Financial: Neutral target Rs 298. Kotak Securities: Neutral target Rs 272. These Mangalam Drugs share price prediction estimates may or may not prove accurate.

Where can I track the latest Mangalam Drugs stock prediction?

Ans. Track the latest analyst targets and price movements for Mangalam Drugs on the NSE and BSE websites and on the Univest app and screener for live data.